|
Fig. 11 Antitumor efficacy of 6 and Lipo-6 in mice bearing the A549 human lung xenograft. (a) Schematic of the A549 xenograft model establishment and treatment schedule. (b) Tumor volume of different treatment groups (n = 5 per group) during the treatment period. (c) Tumor weight of different groups on day 20. (d) Average body weight of mice of different treatment groups. (e) Biodistribution of 6 and Lipo-6, 18 h post last injection showing ∼11-fold higher Ir in tumor and blood for Lipo-6 as compared to complex 6 (see Table S5 in ESI for complete data). Data shown as the mean ± SEM (n = 5 for all groups up to day 20, except the group treated with Lipo-6 where n = 5 up to day 18 and n = 4 on day 20); *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. Note: the data in 11b, 11c, and 11d for vehicle saline- and cisplatin-treated groups are reproduced with permission from ref 53. Copyright [2023] [John Wiley and Sons]. Because the in vivo study of 6 and a few other anticancer agents including cisplatin were performed together, only one vehicle-treated group and one cisplatin-treated group as a positive control were used for all treatment groups to minimize the number of mice used for ethical reasons.